SFPM(SZ:002737)2025-04-25 08:40Group 1: Financial Performance - In 2024, the company achieved operating revenue of 3.377 billion yuan, a year-on-year decrease of 40.76% [2] - The net profit attributable to shareholders of the parent company was 492 million yuan, down 56.03% compared to the previous year [2] - The proposed cash dividend for 2024 is 5 yuan (including tax) per 10 shares, totaling 59.34% of the net profit attributable to shareholders [2] Group 2: Strategic Adjustments - The company is focusing on channel optimization and has established a self-operated B2B platform "Yao Zhida" to enhance efficiency [3] - The strategic direction remains centered on "one elderly, one child, one woman," with an emphasis on chronic diseases and health products [3] - The company plans to expand its product lines in cardiovascular and rheumatic pain areas while maintaining its strengths in digestive system products [3] Group 3: Market Adaptation - The company is adapting to demographic changes, particularly the aging population, by enhancing its product positioning in the elderly care sector [3] - New sales strategies for products like ibuprofen suspension and polyethylene glycol 3350 are being developed to leverage market opportunities [3] - The company is exploring new sales channels, including self-operated e-commerce and direct supply to terminals, to create a multi-dimensional channel system [3] Group 4: Investor Relations - The company emphasizes continuous returns to investors, having distributed dividends exceeding the IPO financing amount since its listing [3] - The management remains committed to maintaining a sustainable return strategy while considering the company's operational status [3] - The company aims to improve operational efficiency and quality through effective implementation of its strategies, ensuring long-term healthy development [3]